TARA is trading at $4.01 (+5.10%) as buyers step in following a JPMorgan price-target note and a technical rebound from the June 30 selloff.
- The move appears to be a sentiment-driven bounce rather than a response to new fundamental catalysts, as no major earnings, FDA announcements, or deals were reported.
- Recent analyst coverage from JPMorgan has provided a price-target update, contributing to the positive momentum amid broader volatility in the small-cap biotech sector.